Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

TargED Biopharmaceuticals, a Netherlands-based thermobolytic clot treatment spinout of UMC Utrecht, picked up €39m ($44.2m) in a series A round today backed by the UMC-backed Utrecht Health Seed Fund. The round was co-led by Andrea Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures. It also included BioGeneration Ventures-managed First Fund and Curie Capital. TargED had secured $1.7m in seed funding in 2020 from investors also including Utrecht Health Seed Fund.

Porotech, a UK-based microdisplay technology…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).